Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

Fineline Cube Jul 14, 2026
Company Deals

GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures

Fineline Cube Jul 14, 2026
Company Deals

Zhaoke Ophthalmology Acquires Global Rights to NVK002 for Myopia Control, Licenses U.S. Rights to Nevakar

Fineline Cube Jul 14, 2026
Company Deals

Sisram Medical Restructures DaxibotulinumtoxinA Partnership with Fosun Wanbang Through New Sublicense and Promotion Services Agreements

Fineline Cube Jul 13, 2026
Company Deals

Teva Secures Global Rights to Polpharma Biologics’ Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio

Fineline Cube Jul 13, 2026
Policy / Regulatory

China’s National Health Commission Launches Comprehensive Continuous Medication Management Framework to Enhance Patient Safety and Healthcare Quality

Fineline Cube Jul 13, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer

Fineline Cube Jul 14, 2026
Company Drug

Fosun Pharma Secures NMPA Approval for Phase 1 Trial of HLX37 Bispecific Antibody in Combination Therapies for Advanced Solid Tumors

Fineline Cube Jul 14, 2026
Company

Pfizer Launches SGD 1 Billion API Plant Expansion in Singapore, Creating 250 New Jobs

Fineline Cube Jul 24, 2024

Pfizer Inc., (NYSE: PFE) a leading global pharmaceutical company, has announced the opening of an...

Policy / Regulatory

China’s NHSA Updates DRG/DIP Payment Reform Program with New Exclusion Mechanisms and Timelines

Fineline Cube Jul 23, 2024

The National Healthcare Security Administration (NHSA) in China has issued a notification outlining several updates...

Company Drug

Jiangsu Hansoh’s Loxenatide Matches Dapagliflozin in Diabetes Nephropathy Clinical Trial

Fineline Cube Jul 23, 2024

Jiangsu Hansoh Pharmaceutical Co., Ltd, a leading pharmaceutical company based in China, has published the...

Company Deals

Innovax Biotech and GSK Terminate Collaboration on Next-Generation HPV Vaccine

Fineline Cube Jul 23, 2024

Xiamen Innovax Biotech Co., Ltd., a Chinese biopharmaceutical company, and GlaxoSmithKline (GSK, NYSE: GSK), a...

Company Drug

China’s NMPA Considers Breakthrough Designations for Xiangxue and Innostellar’s Therapies

Fineline Cube Jul 23, 2024

Xiangxue Pharmaceutical Co., Ltd (SHE: 300147) and Innostellar Biotherapeutics Co., Ltd have both been noted...

Company Deals

Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy

Fineline Cube Jul 23, 2024

Aligos Therapeutics Inc. (NASDAQ: ALGS), a San Francisco-based biotechnology company, has announced a clinical trial...

Company Drug

Johnson & Johnson Pursues FDA Approval for Spravato as Monotherapy for Treatment-Resistant Depression

Fineline Cube Jul 23, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a leading global healthcare company, is pursuing expanded approval...

Company Policy / Regulatory

WuXi AppTec Spends Over USD 360,000 on US Lobbying Amid Biosecure Act Deliberations

Fineline Cube Jul 23, 2024

Endpoints News has reported that WuXi AppTec Co., Ltd, (SHA: 603259) a China-based Contract Development...

Company

Sino Biopharm’s Subsidiary invoX Restructures, Focusing on CD137/PD-L1 Molecule FS222

Fineline Cube Jul 23, 2024

UK-based biotechnology company invoX, an international subsidiary established by China-based Sino Biopharmaceutical Group in 2021,...

Company Deals

China’s Triastek and Germany’s BioNTech Join Forces for 3D Printed Oral Therapeutics

Fineline Cube Jul 23, 2024

Triastek Inc., a China-based pharmaceutical company specializing in 3D printing technology, has entered into a...

Company Drug

RemeGen’s Telitacicept Earns Full NMPA Approval for RA Treatment and PMN Clinical Study Green Light

Fineline Cube Jul 23, 2024

RemeGen (HKG: 9995), a biopharmaceutical company based in China, has announced that the National Medical...

Policy / Regulatory

NMPA Suspends Import and Sale of SAMO S.p.A Knee and Hip Prosthesis Systems

Fineline Cube Jul 23, 2024

The National Medical Products Administration (NMPA) has issued a notice to suspend the import, sale,...

Company Deals

Fosun Pharma and Kite Pharma Inject USD 28.5 Million into Joint Venture for CAR-T Therapy Development

Fineline Cube Jul 23, 2024

Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196) and Kite Pharma, a subsidiary...

Company Deals

Shanghai Medicilon and Jiangsu Hengrui Join Forces to Advance Pre-Clinical Drug Evaluation

Fineline Cube Jul 23, 2024

Shanghai Medicilon Biomedical Co., Ltd, a leading biopharmaceutical company based in China, has entered into...

Company Drug

AccurEdit Therapeutics Receives CDE Approval for Gene Editing Drug ART001 Targeting Amyloidosis

Fineline Cube Jul 23, 2024

AccurEdit Therapeutics (Suzhou) Co., Ltd, a leading specialist in gene editing therapies based in China,...

Company Deals

Luye Pharma Group Secures RMB 1.6 Billion Investment to Boost Financials and R&D

Fineline Cube Jul 23, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...

Company Drug

ICER Analysis Flags Pfizer’s ATTR-CM Therapy Vyndamax/Vyndaqel as Costly, Suggests Price Cut

Fineline Cube Jul 22, 2024

The Institute for Clinical and Economic Review (ICER), a US-based non-profit organization specializing in drug...

R&D

Beijing Launches Bio-Park: A New Hub for International Pharmaceutical Innovation

Fineline Cube Jul 22, 2024

Beijing has unveiled an ambitious plan to construct Bio-Park, a state-of-the-art international pharmaceutical innovation park...

Company Deals Medical Device

MicroPort CardioFlow Secures Exclusive Distribution Rights for Evermend Occluders in China

Fineline Cube Jul 22, 2024

MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced...

Policy / Regulatory

China’s NMPA and NHC Implement New Rules for Temporary Import of Urgent Medical Devices

Fineline Cube Jul 22, 2024

The National Medical Products Administration (NMPA) and the National Health Commission have issued the Management...

Posts pagination

1 … 354 355 356 … 694

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer
  • Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC
  • GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures
  • Fosun Pharma Secures NMPA Approval for Phase 1 Trial of HLX37 Bispecific Antibody in Combination Therapies for Advanced Solid Tumors
  • Zhaoke Ophthalmology Acquires Global Rights to NVK002 for Myopia Control, Licenses U.S. Rights to Nevakar
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Breakthrough Therapy Designation for HRS-7058 in KRAS G12C-Mutant Pancreatic Cancer

Company Deals

Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC

Company Deals

GSK Terminates $2.2 Billion Neurodegenerative Disease Partnership with Alector Following Dual Clinical Failures

Company Drug

Fosun Pharma Secures NMPA Approval for Phase 1 Trial of HLX37 Bispecific Antibody in Combination Therapies for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.